The Lupus Research Alliance (LRA) is inviting applications for its Dr. William E. Paul Distinguished Innovator Awards in Lupus and Autoimmunity program, a global initiative designed to provide outstanding scientists with support needed to conduct novel research into the fundamental causes of lupus.
At present, therapy for lupus is empiric and involves a variety of non-specific anti-inflammatory and immunosuppressive agents. While these treatments are frequently beneficial, many patients do not respond adequately and suffer significant side effects. Importantly, many unanswered questions regarding the pathogenesis of lupus remain and new conceptual and therapeutic approaches are urgently needed. To that end, LRA welcomes novel, hypothesis- or discovery-driven proposals using clinically relevant models in lupus research. The research proposal must aim to uncover the fundamental causes of lupus and present a compelling vision of how the discovery would lay the groundwork for a cure, prevention, or highly effective therapy. In this round of funding, LRI expects to award grants of up to $250,000 per year for up to four years.
Successful applicants will be outstanding investigators who have demonstrated creativity and productivity in their field of research. Applications from investigators in diverse disciplines including but not limited to immunology, genetics, molecular-, cell- and systems biology, are encouraged. Scientists who have not previously worked in lupus are also encouraged to apply, as are researchers working outside the United States. Applicants must hold a position at an academic institution.
Letters of Intent must be received no later than March 16. Upon review, selected applicants will be invited to submit full applications by June 30, 2020.
See the Lupus Research Alliance website for complete program guidelines, information about previous grant recipients, and application instructions.